Although the activity of FLT3 inhibitors in FLT3 WT AML patients may seem surprising, the phase 2 QUIWI trial (NCT04107727) designed by the PETHEMA group, has already shown the activity of FLT3 inhibitors in these patients.27 This evidence concerns the gene FLT3 and acute myeloid leukemia.